Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FMCG out of favour today
Mon, 1 Sep 01:30 pm

Indian share markets continued to trade higher in the post-noon trading session. Barring FMCG, all the sectoral indices are trading in the green with capital goods and power stocks being the biggest gainers.

BSE-Sensex is up 196 points and NSE-Nifty is trading 60 points up. BSE Mid Cap is trading 1.1% up and BSE Small Cap index is trading up by 0.9%. The rupee is trading at 60.46 to the US dollar.

Majority of the auto stocks are trading in the green with Hero MotoCorp and Maruti Suzuki being among major gainers. Tata Motors and Maharashtra Scooters are among the only stocks trading in the red. As per a leading financial daily, Maruti Suzuki reported a 27% YoY jump in sales to 1.1 lakh units in August 2014. Backed by robust performance by the compact car segment (Swift, Ritz, Dzire, Celerio) that saw a 53% surge in sales as well as a 114% jump in super compact segment (Dzire Tour) sales, passenger car sales grew by 30% YoY to 82,832 units in August 2014. On the export front, sales increased by 10.3% YoY to 12,472 units for the month. Maruti Suzuki stock is currently trading up by 3.3%.

Most of the FMCG stocks are trading firm led by Gillette and Emami. Dabur and Hindustan Unilever are among the few stocks trading in the red. As per a leading business daily, the central government will be commissioning a study to provide a boost to the export revenues of herbal drug manufacturing industry. The Department of ayurveda, yoga,unani, siddha and homeopathy (Ayush) will commission a detailed study by a market consultant. The study will determine the demand supply dynamics of medicinal plants in India and international markets, get up-to-date data on cultivation, land available and required and production. The National Medicinal Plant Board will oversee the project and create a policy framework for infrastructure, incentives and other mechanisms. This data will then be used by the government to create special economic zones to promote the sector. This move is likely to benefit companies like Dabur, Emami (Zandu), Himalaya and Charak and a host of small entities and cultivators of herbal plants.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "FMCG out of favour today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.